Abstract

Background. Atopic dermatitis (AD) substantially burdens individuals, families, and healthcare systems. We aimed to document the treatment journey of pediatric patients with moderate-to-severe AD in a referral center based in our country.

Methods. This retrospective study reviewed patients aged 1-18 years diagnosed with AD, seeking systemic treatment recommendations from the “pediatric allergy and dermatology multidisciplinary team meeting”.

Results. Over the 14-month study period, 30 (12.5%) of 240 AD patients were evaluated in the pediatric dermato-allergy team meetings. The median age of the patients was 13.66 years (Q1-Q3: 7.94-17.27), of whom 60% were male. The median annual healthcare visits for AD were 4 (Q1-Q3: 1.00-8.75). Among the study group, 70% were sensitized to aeroallergens, and admission markers included total IgE (median: 1980 IU/mL, Q1-Q3: 794.50-5446), and eosinophil counts (median: 650, Q1-Q3: 275-1275). All patients utilized intermittent and/or continuous topical corticosteroids (CS), with 56.6% employing short-term/long-term topical tacrolimus. Over the past two years, systemic CSs were utilized in 93.3% of the patients, whereas 57.1% received more than one course. Approximately 43.3% of the patients agreed to receive systemic cyclosporine treatment, with only 30.8% benefiting and 3.3% reporting adverse effects (hypertrichosis and cellulitis). Three patients self-funded dupilumab, all benefiting without adverse effects. Omalizumab, mycophenolate mofetil and narrow-band  ultraviolet (UV) treatments were used in one patient each, with limited benefit observed. Health insurance did not grant approval for a Janus kinase inhibitor for one patient.

Conclusions. Managing moderate to severe AD is complex and costly, considering disease heterogeneity, comorbidities, care pathways, and health system challenges. Addressing the unmet needs should be a priority in Türkiye’s healthcare systems.

Keywords: adolescent, atopic dermatitis, children, healthcare, systemic, treatment

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
İlgün Gürel D, Ünsal H, Soyak Aytekin E, et al. The treatment journey of children with moderate to severe atopic dermatitis in Türkiye: unmet needs. Turk J Pediatr 2024; 66: 265-274. https://doi.org/10.24953/turkjpediatr.2024.4569

References

  1. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract 2020; 8: 91-101. https://doi.org/10.1016/j.jaip.2019.06.044
  2. Kiken DA, Silverberg NB. Atopic dermatitis in children, part 1: epidemiology, clinical features, and complications. Cutis 2006; 78: 241-247.
  3. Glines KR, Stiff KM, Freeze M, Cline A, Strowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Expert Opin Pharmacother 2019; 20: 621-629. https://doi.org/10.1080/14656566.2018.1561868
  4. Worm M, Francuzik W, Kraft M, Alexiou A. Modern therapies in atopic dermatitis: biologics and small molecule drugs. J Dtsch Dermatol Ges 2020; 18: 1085-1092. https://doi.org/10.1111/ddg.14175
  5. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36: 1904-1926. https://doi.org/10.1111/jdv.18429
  6. Silverberg JI. Atopic dermatitis treatment: current state of the art and emerging therapies. Allergy Asthma Proc 2017; 38: 243-249. https://doi.org/10.2500/aap.2017.38.4054
  7. Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol 2020; 83: 375-381. https://doi.org/10.1016/j.jaad.2020.03.075
  8. Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med 2023; 33: 7. https://doi.org/10.1038/s41533-023-00330-1
  9. Chipps BE, Murphy KR, Oppenheimer J. 2020 NAEPP guidelines update and GINA 2021-asthma care differences, overlap, and challenges. J Allergy Clin Immunol Pract 2022; 10: S19-S30. https://doi.org/10.1016/j.jaip.2021.10.032
  10. Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol 2020; 145: 70-80.e3. https://doi.org/10.1016/j.jaci.2019.06.049
  11. Kahveci M, Karabulut E, Soyer O, Sahiner UM, Buyuktiryaki B, Sekerel BE. Fine-tuning the use of a skin prick test device. World Allergy Organ J 2020; 13: 100122. https://doi.org/10.1016/j.waojou.2020.100122
  12. Akarsu A, Ocak M, Köken G, Şahiner ÜM, Soyer Ö, Şekerel BE. IgE mediated food allergy in Turkey: different spectrum, similar outcome. Turk J Pediatr 2021; 63: 554-563. https://doi.org/10.24953/turkjped.2021.04.002
  13. de Graaf M, Janmohamed SR, Schuttelaar MLA, et al. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol 2022; 36: 2153-2165. https://doi.org/10.1111/jdv.18410
  14. Civelek E, Sahiner UM, Yüksel H, et al. Prevalence, burden, and risk factors of atopic eczema in schoolchildren aged 10-11 years: a national multicenter study. J Investig Allergol Clin Immunol 2011; 21: 270-277.
  15. Mancuso JB, Lee SS, Paller AS, Ohya Y, Eichenfield LF. Management of severe atopic dermatitis in pediatric patients. J Allergy Clin Immunol Pract 2021; 9: 1462-1471. https://doi.org/10.1016/j.jaip.2021.02.017
  16. Elias PM. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann Allergy Asthma Immunol 2022; 128: 505-511. https://doi.org/10.1016/j.anai.2022.01.012
  17. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132. https://doi.org/10.1016/j.jaad.2014.03.023
  18. Kondratuk K, Netravali IA, Castelo-Soccio L. Modern interventions for pediatric atopic dermatitis: an updated pharmacologic approach. Dermatol Ther (Heidelb) 2023; 13: 367-389. https://doi.org/10.1007/s13555-022-00868-x
  19. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409-1431. https://doi.org/10.1111/jdv.18345
  20. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 139-147. https://doi.org/10.1016/j.jaad.2020.08.051
  21. Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int 2022; 71: 40-46. https://doi.org/10.1016/j.alit.2021.10.004
  22. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682. https://doi.org/10.1111/jdv.14891
  23. Esenboga S, Cetinkaya PG, Sahiner N, et al. Infantile atopic dermatitis: Serum vitamin D, zinc and TARC levels and their relationship with disease phenotype and severity. Allergol Immunopathol (Madr) 2021; 49: 162-168. https://doi.org/10.15586/aei.v49i3.191
  24. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am 2010; 30: 269-280. https://doi.org/10.1016/j.iac.2010.06.003
  25. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: 417-428.e2. https://doi.org/10.1016/j.anai.2020.12.020
  26. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004; 113: 925-931. https://doi.org/10.1016/j.jaci.2004.01.778